Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

intervet international b.v., podružnica u republici hrvatskoj, ivana lučića 2a, 10000 zagreb, hrvatska - inaktivirane stanice listonella (vibrio) anguillarum, soj 78-skid i inaktivirane stanice vibrio ordalii, soj msc 275 - oralna emulzija - imunološki vmp - kalifornijske pastrve (oncorhynchus mykiss)

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

intervet international b.v., podružnica u republici hrvatskoj, ivana lučića 2a, 10000 zagreb, hrvatska - inaktivirane stanice listonella (vibrio) anguillarum, soj 78-skid i inaktivirane stanice vibrio ordalii, soj msc 275 - koncentrat za suspenziju za kupku i suspenzija za intraperitonealnu injekciju - kalifornijske pastrve (oncorhynchus mykiss)

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

pharmaq as skogmo industriområde, industrivegen 50, 7863 overhalla, norveška - inaktivirana listonella anguillarum (vibrio anguillarum), serotip o1, soj al 112 - koncentrat za suspenziju za kupku - inaktivirana listonella anguillarum (vibrio anguillarum), serotip o1, soj al 112 - lubina (dicentrarchus labrax l)

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

pharmaq as, skogmo industriområde, industrivegen 50, 7863 overhalla, norveška - inaktivirana listonella anguillarum (vibrio anguillarum), serotip o1, soj al 112 inaktivirana photobacterium damselae subsp. piscicida, soj al 5051 - emulzija za injekciju - inaktivirana listonella anguillarum (vibrio anguillarum), serotip o1, soj al 112 inaktivirana photobacterium damselae subsp. piscicida, soj al 5051 - brancina (dicentrarchus labrax)

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

zik-90 d.o.o., varaždin, hrvatska - c12-16-alkildimetil-benzilamonijev klorid, didecildimetil-benzilamonijev klorid, izopropanol i glutaraldehid - koncentrirana otopina za pripremu radne otopine s vodom - dezinfekciji radnih površina, predmeta i opreme u stočarskoj proizvodnji

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - tablete orkambi rezultati za liječenje муковисцидоза (mv) kod bolesnika u dobi od 6 i više godina, koji su гомозиготами na mutacije f508del u genu cftr . orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Europska Unija - hrvatski - EMA (European Medicines Agency)

roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresivi - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.